Nelli Aleksandrovna Kashchavtseva

Nelli Aleksandrovna Kashchavtseva

Auto-generated profile, based on publicly available information

Nelli Aleksandrovna Kashchavtseva

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NKN A Kashchavtseva
N A Kashchavtseva
IRI G Rekhtina
I G Rekhtina
AKA M Kovrigina
A M Kovrigina
TDT P Danilina
T P Danilina
LML P Mendeleeva
L P Mendeleeva
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face. Tumor masses consisted of amyloid masses in which single monotypic plasma cells were "embedded". To verify the cell substrate, the method of chromogenic in situ hybridization with probes to immunoglobulin light chains was used. Amyloid typing was performed using FITC-labeled antibodies to kappa and lambda light chains after enzymatic treatment of paraffin sections with pronase. The absence of monoclonal secretion (in two cases) made it difficult to assess the efficacy of the therapy. Taking into account the prevalence and severity of vital organs damage, as well as the recurrent nature of the disease course, systemic combination therapy with targeted drugs was prescribed. Stabilization of the process in all patients was stated during one year of follow-up. Nevertheless, clonreducing therapy in localized AL amyloidosis is not considered as a standard option, its feasibility and efficacy requires further confirmation.

19 March 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
NKN. A. Kashchavtseva
N. A. Kashchavtseva
IRI. G. Rekhtina
I. G. Rekhtina
IGI. V. Galtseva
I. V. Galtseva
NKNikolay Kapranov
Nikolay Kapranov
KNKsenya Nikiforova
Ksenya Nikiforova
LML. P. Mendeleeva
L. P. Mendeleeva
Immunophenotypic features of plasma cells (pC) in patients with systemic AL‑amyloidosis (AL‑A) are not fully characterized. The bone marrow of 113 patients with first diagnosed systemic AL‑A was studied by 10‑color flow cytofluorimetry. Three densities of differentiation antigen expression were distinguished: negative – less than 10 % of aberrant cells expressed antigen, partial – 10–90 % of cells expressed antigen, positive – more than 90 % of cells expressed antigen. Patients were divided into three groups. Group 1 included 76 patients with AL‑A and a PC count of less than 10 %. The second group consisted of 25 patients with a PC count greater than 10 % but without evidences of symptomatic multiple myeloma. The third group included 12 patients with a PC count greater than 10 % and symptomatic CRAb (AL‑A combined with multiple myeloma). 75 patients received first‑line therapy, including bortezomib, cyclophosphamide, and dexamethasone. When comparing the immunophenotype of aberrant PCs of each individual patient by means of a heat map, no complete match was found in any case, which confirms the uniqueness of clonal PC biology and their high heterogeneity. It was found that aberrant PCs lost expression of CD19 in 95.6 % of cases, CD45 in 78.6 % of patients, CD81 in 37.5 %, and CD27 in 36 %. CD20 was expressed in 7.7 % of patients, CD56 in 48.2 %, and CD117 in 36.8 %. A positive but low (dim) density of CD38 expression was detected in 45 % of patients. There were no statistically significant differences in the expression profile of CD19, CD20, CD27, CD38, CD45, CD56, CD117, CD138, CD200, and CD319 between the patient groups. The frequency of CD269 (bCMA) expression on pC varied depending on the size of the morphologic substrate. Partial expression of Cd269 (bCMA) was detected in 46.7 % of patients in group 1; 84.7 % in group 2 and 100 % in group 3 (p = 0.02). No positive, including high, Cd269 expression, was detected in any AL‑A patient in all three groups. A negative correlation of CD27 expression with the depth of hematologic response on therapy with bortezomib was established: in the absence of CD27 expression, a deep hematologic response was achieved in 87.5 % of cases, and with positive expression of this marker in only 35 % of patients (p = 0.02).

1 October 2026 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
NKNelli Aleksandrovna Kashchavtseva
Nelli Aleksandrovna Kashchavtseva
IRI. G. Rekhtina
I. G. Rekhtina
IGI. V. Galtseva
I. V. Galtseva
LML. P. Mendeleeva
L. P. Mendeleeva
BACKGROUND. In 8–20 % of patients with systemic AL amyloidosis (AL-A), a non-measurable disease is diagnosed which is characterized by low serum concentration of paraprotein and free light chains (FLCs). The standard immunochemical methods are not sufficiently robust in such clinical situation to evaluate the response to therapy and subsequent monitoring of the disease. AIM. To compare clinical and laboratory characteristics of AL-A patients with measurable and non-measurable diseases as well as to estimate the diagnostic value of multicolor flow cytometry of bone marrow (BM) in non-measurable AL-A. MATERIALS & METHODS. This prospective study enrolled 108 patients with newly diagnosed systemic AL-А, 20 (18.5 %) of them with a non-measurable disease (the difference between involved and uninvolved FLCs < 50 mg/L, paraprotein level < 10 g/L). All patients underwent clinical and laboratory examination including immunochemical analysis and 10-color flow cytometry of BM. RESULTS. In patients with non-measurable AL-A, severe cardiac failures occurred significantly less frequently (stage III: 16.7 % vs. 33.4 %; p = 0.03), whereas the rates of kidney and other organ involvements did not considerably differ. The median plasma cell (PC) count in non-measurable and measurable AL-A was 3.4 % and 5.2 %, respectively (p = 0.36) with the proportion of aberrant PCs in the total PC count being significantly lower in non-measurable disease (median 70.0 % vs. 92.2 %; p = 0.01). No correlation between the involved FLC concentration and the number of aberrant PCs was observed in non-measurable AL-A, while in measurable disease this correlation appeared to be significant (p = 0.003). The study demonstrated that the changes in aberrant PC clone by flow cytometry better correlated with the clinical response than with the changes of immunochemical parameters. Thus, the 5-year overall survival of patients with non-measurable and measurable AL-A did not differ (68 % and 61 %, respectively; p = 0.77). However, the 4-year clinical-progression-free (without vital organ dysfunction) survival was significantly lower in non-measurable disease, i.e., 23 % vs. 47 % (p = 0.04), which demonstrates that the standard immunochemical criteria alone used for response evaluation cannot provide sufficient control of the disease. CONCLUSION. Multicolor flow cytometry of BM is an effective additional method of diagnosis and monitoring of non-measurable AL-A disease, which allows to determine the tumor clone and objectively assess the therapy efficacy in cases when immunochemical methods appear to be limited. It seems to be advisable to regard flow cytometry as part of standard examination for this category of patients aiming to improve the accuracy of diagnosis and the evaluation of hematologic response.